All Videos

Dr Christopher Bunick discusses the role the microbiome and sebum play in acne production and highlights the role Clascoterone cream 1% plays in targeting these agents.

Christopher Bunick, MD, PhD, provides an overview of acne vulgaris and the populations it impacts; highlighting that this is more than just an adolescent affliction and the role of sebum production.

Andrew Blauvelt, MD, MBA, reviews systemic vs topical treatment of AD, discussion patient preferences as a factor for treatment selection.

Experts in dermatology discuss the rapidly expanding treatment landscape of atopic dermatitis and how these new treatment options have changed the management of AD.

An expert in dermatology reviews the differences in Isotretinoin and highlights how this treatment is both highly efficacious and safe when administered and monitored properly.

Dr Hilary Baldwin stresses the importance of defining severe acne and the utility of isotretinoin in this patient focusing on dosing and administration considerations.

Hilary Baldwin, MD, provides a recap of a panel discussion surrounding the optimal use of Clascoterone cream 1%, highlighting the ubiquity of this treatment.

An expert in dermatology shares his insights into some hot topics in skin renewal and highlights the utility of retinols in this arena.

Ted Lain, MD, MBA, comments on the rise of skin renewal research, cosmeceuticals, and tailored skin care regimes in between sessions at AAD.

An expert in dermatology reviews the differences in Isotretinoin and highlights utilization requirements in patients prescribed this treatment.

Dr James Q Del Rosso discusses the benefit of combination therapy in the management of acne and highlights the importance of combating acne scarring.

James Q Del Rosso, DO, shares his insight into some causes of acne and the utility of clascoterone cream 1% combat this condition in both male and female patient populations.

An expert in dermatology shares her thoughts on the role and efficacy of hydrophobically-modified polymers and green cleansing technologies comparing them to more traditional methods at AAD.

Patricia Farris, MD, discusses the importance of gentle cleansing techniques and hydrophobically modified polymers, highlighting their role in patients with sensitive skin in between sessions at AAD.

An expert in dermatology shares her thoughts at AAD on the sun protection needs in her patients with skin of color; highlighting the role of the Fitzpatrick skin type scale and compounds such as vitamin E and antioxidants.

Amy McMichael, MD shares her insights on the role of tinted sunscreens for patients with darker skin tones, and discusses the need to protect against UVA, UVB, and visible light in between sessions at AAD.

Experts in dermatology discuss their use cases of cemiplimab and reinforce the need for dermatologists to utilize novel and effective treatments within their patient populations.

Dr Aaron Farberg discusses the role of cemiplimab in the management of BCC; highlighting the need to increase the engagement of a multidisciplinary team in the use of this treatment.

Neal Bhatia, MD, and Aaron Farberg, MD, discuss the progression of basal carcinoma and the evolving treatment approaches to this condition.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, summarize the TRuE-AD1 and TRuE AD2 phase 3 trial and provide take home messages topical ruxolitinib cream for the treatment of atopic dermatitis.

Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss take a closer look at the TRuE-AD1 and TRuE AD2 phase 3 trial and provide context regarding ruxolitinib cream for the treatment of atopic dermatitis in the clinical setting.

James Q Del Rosso, DO, takes a closer look at the trial data regarding timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis.

Experts in dermatology comment on their considerations relating to treatment selection in their patients with basal cell carcinoma, highlighting the impact of cemipulab in this space.

Laura Ferris, MD, PhD and Andrew Weinstein, MD, FAAD discuss the importance of multidisciplinary care in their patients with locally advanced basal cell carcinoma, reinforcing the role of the dermatologist in the care plan.

An expert in dermatology shares practice pearls at AAD for how to combine both over the counter and prescription acne medications in those patients suffering from acne.

Joshua Zeichner, MD discusses the burden of acne in his patients and provides his best practices for setting and managing treatment expectations with over the counter and prescription treatment options in between sessions at AAD.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss the week 8 change results of ruxolitinib cream from the TRuE-AD1 and TRuE AD2 phase 3 trial.

Thought leaders provide an overview of the basline characteristics of the TRuE-AD1 and TRuE AD2 phase 3 trial.

An expert in dermatology shares his thoughts on the educational and unmet needs in the identification and management of patients with GPP.

Dr David Kaplan discusses the current treatment options for GPP; highlighting the long time to treatment repose, need for combination treatment, and of standard of care guidelines.